BioSpace News Archive

Codex DNA, Inc., creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, announced the pricing of its initial public offering of 6,666,665 shares of its common stock at a public offering price of $16.00 per share.

Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics, announced the pricing of its initial public offering of 7,000,000 American depositary shares, each representing seven ordinary shares, at a public offering price of $18.00 per ADS.

atai Life Sciences B.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share.